Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05870761 · ClinicalTrials.gov registry record · Phase 2
Combination Niraparib and Dostarlimab Therapy for Recurrent or Persistent Uterine Serous Carcinoma
A Phase 2 study of Recurrent Endometrial Serous Adenocarcinoma, sponsored by Casey Cosgrove.
- Active
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
- 1
- Study location
NCT05870761: Active Phase 2 study of Recurrent Endometrial Serous Adenocarcinoma, sponsored by Casey Cosgrove.
NCT05870761 is a Phase 2 study of Recurrent Endometrial Serous Adenocarcinoma that is active but no longer recruiting, run by Casey Cosgrove. The registered enrollment target is 8 participants, below the 43-participant average among 3 other Recurrent Endometrial Serous Adenocarcinoma trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05870761, a Phase 2 study of Recurrent Endometrial Serous Adenocarcinoma, is active but no longer recruiting, sponsored by Casey Cosgrove.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial tests how well niraparib and dostarlimab work in treating patients with uterine serous carcinoma that has come back (after a period of improvement) (recurrent) and remains despite treatment (persistent). Niraparib belongs to a class of drugs called PARP inhibitors that prevent cancer cells from growing. Dostarlimab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. Dostarlimab belongs to a class of drugs called PD-1 inhibitors that uses the patient's own immune system to treat cancer (immuno-therapy). Giving niraparib and dostarlimab may work better in treating patients with uterine serous carcinoma.
Primary Outcome
Defined as the percentage of patients with complete response (CR), or partial response (PR), as assessed by Response Evaluation Criteria in Solid Tumors (RECIST) version (v.) 1.1 criteria using investigator's review. Will be estimated and reported with 95% confidence intervals (exact).
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- PROCEDURE Computed Tomography
- PROCEDURE Magnetic Resonance Imaging
- DRUG Niraparib
- BIOLOGICAL Dostarlimab
Study Locations (1)
Ohio
- Ohio State University Comprehensive Cancer Center - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2023-10-17 |
| Est. Completion | 2025-12-31 |
| Phase | Phase 2 |
What the registry record for NCT05870761 still lists
NCT05870761 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 43-participant average among 3 other Recurrent Endometrial Serous Adenocarcinoma trials with a reported enrollment target (81% lower).
The record links to 1 condition, with Recurrent Endometrial Serous Adenocarcinoma appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.
NCT05870761 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT05870761 about?
NCT05870761 is a clinical study titled "Combination Niraparib and Dostarlimab Therapy for Recurrent or Persistent Uterine Serous Carcinoma". This phase II trial tests how well niraparib and dostarlimab work in treating patients with uterine serous carcinoma that has come back (after a period of improvement) (recurrent) and remains despite treatment (persistent). Niraparib belongs to a class of drugs called PARP inhibitors that prevent ca...
What is the current status of trial NCT05870761?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2023-10-17. Estimated completion is 2025-12-31.
What conditions does trial NCT05870761 study?
This clinical trial studies the following conditions: Recurrent Endometrial Serous Adenocarcinoma.
What interventions are being tested in trial NCT05870761?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Computed Tomography (PROCEDURE), Magnetic Resonance Imaging (PROCEDURE), Niraparib (DRUG), Dostarlimab (BIOLOGICAL).
Who is sponsoring clinical trial NCT05870761?
This trial is sponsored by Casey Cosgrove, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05870761 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Endometrial Serous Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer
RECRUITING · Phase 2
-
VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Stage IV or Recurrent Endometrial Cancer
ACTIVE NOT RECRUITING · Phase 1
-
Stereotactic Body Radiation Therapy in Treating Patients With Recurrent Primary Ovarian or Uterine Cancer
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI